Ommolbanin Younesian, Behnaz Khodabakhshi, Sara Hosseinzadeh, Seyedeh Somayeh Hosseini Alarzi, Samareh Younesian, Mojtaba Pourmomen, Mana Zakeri, Ali Hosseini, Professor Hamidreza Joshaghani,
Volume 17, Issue 5 (Sep-Oct 2023)
Abstract
Background: Although public health interventions have slowed the spread of SARS CoV 2 infections, the worldwide pandemic of COVID 19 is progressing. Thus, effective and safe vaccination against SARS CoV 2 is an important tool for controlling the COVID 19 pandemic. Now in the early stages of COVID 19 vaccination, vaccinated individuals are interested in using antibody tests to confirm vaccination success and estimate the time of protection. Here, we assessed anti spike IgG responses in the general population 2 weeks after the second dose of the Sputnik V vaccine.
Methods: This study included blood samples of 67 individuals without a previous SARS CoV 2 infection taken 14 days after the second dose of the Sputnik V vaccine. Anti spike IgG responses were assessed with an enzyme linked immunosorbent assay (ELISA).
Results: Anti spike IgG was detected in 55 (82.1%) of 67 samples 14 days after the second dose of the Sputnik V vaccine. Antibody levels were significantly lower in males than in females, and 9 (75%) of 12 seronegative individuals were males.
Conclusion: Vaccination resulted in detectable anti spike IgG in 82.1% of individuals, and gender may be an important factor in the humoral response.
